博尔诚(北京)科技有限公司

About 博尔诚(北京)科技有限公司

BioCerna Group is comprised of BioCerna (Beijing) Technology Co., Ltd. and BioChain Institute, Inc. in the United States. BioCerna (Beijing) Technology Co., Ltd. was founded in 2006 in Zhongguancun, Beijing, focusing on the industrialization of early diagnostic products for major diseases such as cancer. It is one of the pioneers and leaders in China capable of realizing the industrialization of the entire chain for early cancer diagnosis and intervention. BioChain Institute, Inc. was founded in 1994 in Silicon Valley, USA, and is an international company specializing in biological sample processing and products for research and development, with agencies in 48 countries and regions. BioCerna is a high-tech enterprise integrating in-vitro diagnostic products and biological reagents research and development, production, and sales, biomedical transformation, and clinical medical testing services. Since its establishment, the company has adhered to a people-oriented approach, prioritizing quality, focusing on research and development, dedicating itself to service, and giving back to society. The company holds nearly a hundred domestic and international invention patents, exclusive license rights, and priority use rights in the fields of tumor molecular diagnostic reagents, liquid biopsy technology, biological sample processing, and epigenomics. BioCerna has a 40,000 square meter industrialization base in the Beijing Economic-Technological Development Area, with nearly one hundred products holding CFDA approval. The product Septin9 has gradually entered most Class A tertiary hospitals nationwide. BioChain Institute, Inc. has a 4,000 square meter R&D center in Silicon Valley, USA. Its tumor research and development products have served biopharmaceutical diagnostic companies and research institutions in most developed countries and regions. It has also collaborated deeply with top institutions such as Stanford University, University of California, the National Cancer Institute, the Cancer Institute of China, Peking Union Medical College Hospital, and the Cancer Hospital, Chinese Academy of Medical Sciences. The company, in compliance with WTO rules and integrating cutting-edge intellectual property for early cancer diagnosis from Europe, the United States, and China, has achieved full-chain industrialization operations covering independent research and development, clinical trials, registration, production, quality control, sales channels, and customer service. BioCerna (Beijing) Technology Co., Ltd. currently has two wholly-owned subsidiaries: Beijing Modern Gaoda Biotechnology Co., Ltd. and Beijing BioCerna Medical Laboratory Co., Ltd. In terms of R&D, the company has two top-tier R&D teams between China and the United States. The company possesses strong development capabilities in tumor gene methylation, tumor-specific markers, liquid biopsy, and automated sample processing instruments, independently completing the entire process from core raw material development, tumor marker discovery and clinical validation, to product registration and industrialization. Since 2014, it has received two innovation medical device product honors and green channel access.